nuvisertib   Click here for help

GtoPdb Ligand ID: 13215

Synonyms: SGI-9481 | SGI9481 | TP-3654 | TP3654
Compound class: Synthetic organic
Comment: The chemical structure for nuvisertib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a serine/ threonine kinase inhibitor with antineoplastic action. A structure match to clinical lead TP-3654 was made via PubChem. TP-3654 is declared as an orally available, second-generation pan-PIM kinase inhibitor [1-2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 60.22
Molecular weight 418.46
XLogP 3.54
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)([C@@]1([H])CC[C@@]([H])(CC1)NC2=NN3C(=CN=C3C=C2)C4=CC(=CC=C4)C(F)(F)F)O
Isomeric SMILES [H][C@@]1(CC[C@@]([H])(CC1)C(C)(C)O)NC2=NN3C(C=C2)=NC=C3C4=CC=CC(=C4)C(F)(F)F
InChI InChI=1S/C22H25F3N4O/c1-21(2,30)15-6-8-17(9-7-15)27-19-10-11-20-26-13-18(29(20)28-19)14-4-3-5-16(12-14)22(23,24)25/h3-5,10-13,15,17,30H,6-9H2,1-2H3,(H,27,28)/t15-,17-
InChI Key XRNVABDYQLHODA-JCNLHEQBSA-N
No information available.
Summary of Clinical Use Click here for help
TP-3654 is an active clinical candidate.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04176198 A Study of Oral TP-3654 in Patients With Myelofibrosis Phase 1/Phase 2 Interventional Sumitomo Pharma America, Inc.
NCT03715504 Study of TP-3654 in Patients With Advanced Solid Tumors Phase 1 Interventional Sumitomo Pharma America, Inc.